Proteomic approaches for defining oncogene/tumor suppressor protein complexes in tumors are still limited not only by technical issues but also, and perhaps more importantly, by tumor heterogeneity, implying that judicious choice of cellular or computational models will have to reflect the enormous variety of tumors sampled from patients. The gene discussed is TCHP; the disease is neoplasm.